The first clinical association of elevated GAD antibodies was described in 1988, and since then, GAD antibody-spectrum disorders (GADSD) have been recognized, encompassing autoimmune neurological diseases marked by excessive neuronal activity [5]. This evidence concerns the gene GAD1 and autoimmune disorder of the nervous system.